Big Pharms Bribes FDA Regulators to Approve Deadly Drugs
The term “Big Pharma” is a derogatory nickname that encompasses the billion-dollar pharmaceutical companies that are in the business of manufacturing and distributing prescription drugs. Over the years, these companies have earned an unpopular reputation for buying politicians, price gouging the market, funding skewed publications, ghostwriting medical journals, profiting from highly-addictive drugs, and contributing to the opioid epidemic.
Big players in the pharmaceutical industry include:
- Johnson & Johnson
- Eli Lilly
The FDA & Big Pharma: A Dangerous Codependent Relationship
The Food and Drug Administration (FDA) established the Center for Drug Evaluation and Research (CDER) to verify the safety of any prescription and nonprescription drugs being marketed in the United States. When a pharmaceutical company wants to sell a new drug, they must first do extensive testing and send the results to CDER, who in turn assigns a team of chemists, pharmacologists, and other scientists to analyze the documentation.
However, despite conflict of interest rules, many of the independent advisors hired by the FDA are funded by Big Pharma. According to an investigation completed by Science magazine, the funds are distributed after the drugs are approved to protect the advisors from being questioned by FDA officials. As Clark Mindock, a reporter for the Independent, explains, “The analysis of payments, made public through disclosures in scientific publications, found that, of 107 physicians who advised the FDA on 28 drugs that were approved between 2008 and 2014, the majority of them later received financial support – including direct payments for consulting, reimbursements for travel expenses, or other support for research – from the companies whose drugs they voted on.”
On June 27, 2019, Truth In Media’s investigative journalist Ben Swann met with Attorney Mike Papantonio to discuss the “revolving door” relationship between the FDA and Big Pharma. Ring of Fire, a multi-media network devoted to exposing corporate media failures, environmental criminality, and political corruption, posted a transcript of this powerful discussion. Key points from this meeting include:
- The FDA regulator is a “myth.”
- Pharmaceutical companies are the second largest lobbying influence in America.
- 10,000 people in the United States die after using prescription drugs each year, and the media never comments on it because pharmaceutical companies are big advertisers.
- Because the government has capped funding for the FDA, drug companies are engaging in an all-out bidding war to influence the underpaid FDA staff responsible for approving new drugs.
- Drug companies spend billions of dollars to influence FDA regulators, politicians, and corporate media representatives.
- A company will spend over $1 billion to fast-track – and sometimes even bypass – the drug approval process.
- “Once a drug is approved by the FDA, it is rarely ever reviewed after the fact and that means that once a drug gets through, there’s almost no one on the FDA side assigned to going back and saying, “let’s take a look at the drugs that were approved but now have side effects that are harmful and in some cases even deadly.”
- The “dysfunctional” FDA has made it impossible to know if a product has the potential to harm and/or kill a patient.
- The current administration, paid off by Big Pharma, is pressuring the FDA to approve new drugs at a faster rate.
- The FDA is too understaffed to effectively test and monitor the drugs.
Have You Been Harmed by a Drug? Contact The Pittman Firm, P.A. Today
If you’ve suffered harm after taking a defective or recalled drug, contact Attorney Wes Pittman at The Pittman Firm, P.A. Our founding attorney has been representing the victims of Big Pharma for over 30 years. He can help you file a product liability claim and pursue damages that facilitate your ongoing recovery process.
Hold Big Pharma responsible for your injuries. Call The Pittman Firm, P.A. at (850) 784-6997 to schedule a consultation.